Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Cash, Cash Equivalents, Marketable Securities : $41.15 Mil (As of Sep. 2018)

View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities?

Keryx Biopharmaceuticals's quarterly cash, cash equivalents, marketable securities declined from Mar. 2018 ($60.09 Mil) to Jun. 2018 ($49.46 Mil) but then stayed the same from Jun. 2018 ($49.46 Mil) to Sep. 2018 ($41.15 Mil).

Keryx Biopharmaceuticals's annual cash, cash equivalents, marketable securities declined from Dec. 2015 ($200.29 Mil) to Dec. 2016 ($111.81 Mil) and declined from Dec. 2016 ($111.81 Mil) to Dec. 2017 ($93.53 Mil).

Keryx Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Keryx Biopharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

Keryx Biopharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

55.70

85.79

200.29

111.81

93.53

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															114.00	93.53	60.09	49.46	41.15

Keryx Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Keryx Biopharmaceuticals (NAS:KERX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Keryx Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.keryx.com

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Executives

Scott A Holmes	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison	director, officer: Interim CEO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma	director, 10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison	director, officer: President and CEO	ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams	officer: General Counsel and Secretary	750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022